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management in adult patients with refractory epilepsy in Spain.
METHODS: A cross-sectional and retrospective study was
designed. Male and female adult patients (above 18 years) with
refractory epilepsy were enrolled in neurology medical settings
between March and September 2005 in Spain. Health care and
non-health care resources were collected and total costs calcu-
lated according with published prices for year 2005. Quality-of-
life, level of anxiety and depression, health state, concomitant
medications and comorbidity history and treatment of epilepsy
were also recorded. A secondary analysis including a forward
stepwise multivariate regression model exploring possible
explicative variables was performed. RESULTS: Seven-hundred-
sixty-two consecutive patients [728 evaluables (95.5%); 50.8%
males, 40.5 (13.5) years, 24.3 (13.4) years of evolution] were
included through the country at epilepsy units, neurology out-
patient clinics and hospital outpatient clinics. A moderate
explicative model was built; adjusted R-square = 0.24 (F = 26.6,
p < 0.0001). Presence of mental retardation and social function
domain of the QOLIE-10 were the variables with most explica-
tive weight of total cost in these patients; standardized estimates
of 0.303 and 0.175, respectively [â coefﬁcient (standard error)
of 6675.0 (826.8) and 53.5 (12.7), p < 0.001 in both cases
respectively]. Health status on a 0–100 mm-VAS (standardized
estimate; 0.142), need for additional non-neurological hospital
assistance (0.118), previous episode of secondarily generalized
seizures (0.102), health care at neurology outpatient clinics
(0.083), and documented etiology of epilepsy (0.096) were all
found to be signiﬁcant explicative variable, all of them p < 0.05.
CONCLUSIONS: This secondary analysis found a broad sources
of drivers of costs in patients with refractory epilepsy in Spain,
with mental retardation and social function domain of QOLIE-
10 (the higher the score the higher the cost) being responsible
for a substantial part of total cost.
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OBJECTIVE: To estimate the cost-effectiveness of pramipexole
versus no treatment in patients with moderate to very severe rest-
less legs syndrome (RLS) in Sweden taking the societal perspec-
tive. METHODS: A cost-utility Markov model was developed
that included ﬁve health states (no, mild, moderate, severe and
very severe RLS) based on the International RLS Study Group
Rating Scale scores. The probability of moving between health
states was derived from the phase III, randomized, double-blind
pramipexole trials in RLS. To comprehensively estimate quality-
adjusted life years (QALYs) several approaches were taken to
map the IRLS to the EQ-5D including Delphi panel, patient
survey and published literature. Treatment patterns were esti-
mated with a physician expert panel. 2005 unit costs were
derived from Swedish government sources. Both one-way and
probabilistic sensitivity analyses were conducted. RESULTS:
Over a one-year time period, treatment with pramipexole
reduced overall costs by SEK 1191 (approximately €128) per
patient and was associated with a gain of 0.035 QALYs relative
to no treatment when using utilities from the Delphi panel.
Pramipexole’s dominance from the societal perspective against
the no treatment alternative was robust to sensitivity analysis.
Sensitivity analyses included variation in health care provider
costs, different utility assumptions, and an extension of the
model to a ﬁve-year time period. CONCLUSIONS: Active treat-
ment of RLS with pramipexole is preferred over no treatment
for patients with moderate to very severe RLS in Sweden.
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OBJECTIVE: To estimate the cost-utility of levodopa-carbidopa
and levodopa-carbidopa-entacapone in the treatment of Parkin-
son disease in the Mexican Institute of Social Security in Mexico.
METHODS: Cost-utility analysis. Use of resources information
was obtained from a retrospective cohort and was validated by
a Mexican expert panel. Costs were estimated from ﬁnancial
information from IMSS, and are reported in US 2006 dollars.
The source of utility information, measured in QALYs, and 
transition probabilities was a meta-analysis and a Mexican
expert panel. Study perspective used: public health services
provider (IMSS); ﬁve years time horizon, 3% real discount rate.
A decision tree with a Bayesian approach and a Markov model
were used. Mean cost-utility, incremental ratios and net health
beneﬁts were estimated. The sensitivity analysis included one-
way, two-way, threshold and probabilistic with Monte Carlo
simulation. RESULTS: Cost per utility unit for levodopa-
carbidopa was $5623 and for levodopa-carbidopa-entacapone,
$5168. Incremental cost-utility ratio using levodopa-carbidopa
as a comparator was $1585. Independently of WTP, levodopa-
carbidopa-entacapone had larger net health beneﬁts than 
levodopa-carbidopa. In the ﬁve years analysis, levodopa-
carbidopa-entacapone showed 12.8% more utility in relation-
ship to levodopa-carbidopa, with 3.5% more costs. The cost per
utility unit with levodopa-carbidopa-entacapone had an accu-
mulated decrease of 18.4% during the period of time analyzed.
The acceptability curves and the component analysis of the
ellipse graph showed that with the actual cost that the IMSS is
investing in the treatment of Parkinson disease, the cost-utility
proportion of levodopa-carbidopa-entacapone would be 80%.
CONCLUSIONS: Levodopa-carbidopa-entacapone had the
lowest cost per unit of success in the treatment of patients with
Parkinson disease compared with levodopa-carbidopa. Cost per
additional utility unit of levodopa-carbidopa-entacapone was
$1585. At the end of the follow-up levodopa-carbidopa-enta-
capone reduced annual health care costs to a greater extent than
levodopa-carbidopa and provided better quality of life per
patient.
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OBJECTIVE: The objective of this study was to evaluate the
indirect evidence of menstrual migraine headache by examining
migraine headache prevalence as a function of age. Investigators
have reported that the risk of migraine headache decreases with
age but have not fully described the nature of the decline based
on sex. METHODS: This study was based on data from the
adult sample of the 2003 National Health Interview Survey
(NHIS). The study sample consisted of 17,394 females and
